Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis

Seung Woon Park, Soon Ho Um, Han Ah Lee, Sang Hyun Kim, Yura Sim, Sun Young Yim, Yeon Seok Seo, Ho Sang Ryu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.

Original languageEnglish
Pages (from-to)281-285
Number of pages5
JournalClinical and molecular hepatology
Volume22
Issue number2
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Mycophenolic Acid
Autoimmune Hepatitis
Azathioprine
Adrenal Cortex Hormones
Fibrosis
Cyclophilins
Acute Liver Failure
Expert Testimony
Tacrolimus
Therapeutics
Immunosuppressive Agents
Cyclosporine
Liver Diseases
Chronic Disease
Necrosis
Inflammation
Pharmaceutical Preparations

Keywords

  • Autoimmune hepatitis
  • Azathioprine
  • Mycophenolate mofetil

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis. / Park, Seung Woon; Um, Soon Ho; Lee, Han Ah; Kim, Sang Hyun; Sim, Yura; Yim, Sun Young; Seo, Yeon Seok; Ryu, Ho Sang.

In: Clinical and molecular hepatology, Vol. 22, No. 2, 01.06.2016, p. 281-285.

Research output: Contribution to journalArticle

Park, Seung Woon ; Um, Soon Ho ; Lee, Han Ah ; Kim, Sang Hyun ; Sim, Yura ; Yim, Sun Young ; Seo, Yeon Seok ; Ryu, Ho Sang. / Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis. In: Clinical and molecular hepatology. 2016 ; Vol. 22, No. 2. pp. 281-285.
@article{c8beb1f6bb754ae299b02b6e19f79e1a,
title = "Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis",
abstract = "Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.",
keywords = "Autoimmune hepatitis, Azathioprine, Mycophenolate mofetil",
author = "Park, {Seung Woon} and Um, {Soon Ho} and Lee, {Han Ah} and Kim, {Sang Hyun} and Yura Sim and Yim, {Sun Young} and Seo, {Yeon Seok} and Ryu, {Ho Sang}",
year = "2016",
month = "6",
day = "1",
doi = "10.3350/cmh.2015.0040",
language = "English",
volume = "22",
pages = "281--285",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "2",

}

TY - JOUR

T1 - Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis

AU - Park, Seung Woon

AU - Um, Soon Ho

AU - Lee, Han Ah

AU - Kim, Sang Hyun

AU - Sim, Yura

AU - Yim, Sun Young

AU - Seo, Yeon Seok

AU - Ryu, Ho Sang

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.

AB - Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.

KW - Autoimmune hepatitis

KW - Azathioprine

KW - Mycophenolate mofetil

UR - http://www.scopus.com/inward/record.url?scp=84984984975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984984975&partnerID=8YFLogxK

U2 - 10.3350/cmh.2015.0040

DO - 10.3350/cmh.2015.0040

M3 - Article

C2 - 27246353

VL - 22

SP - 281

EP - 285

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 2

ER -